GLPwatch
Papers (9189)
Page 141 of 154, ranked by citation count.
- Semaglutide (Wegovy) for MASH.
- Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review.
- Comparison table: Some drugs for weight management.
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy.
- The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.
- A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus.
- Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis.
- Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols.
- Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.
- [The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy].
- Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study.
- Effect of Tirzepatide on Cardiovascular Outcomes.
- Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.
- GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies.
- ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition.
- Difficult to defeat obesity: An 8D approach.
- Gewichtsabnahme ist mit Semaglutid signifikant grösser als mit Liraglutid.
- [Does liraglutide have a place in psychiatry ?]
- Aktuelles zur Therapie mit GLP-1-Rezeptoragonisten bei Patienten mit Diabetes mellitus Typ 2.
- [Treatment of type 2 diabetes: Exenatide or liraglutide? - Exenatide and liraglutide in head-to-head comparison approximately coequal].
- Preferred GLP-1 Receptor Agonists in Type 2 Diabetes With Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-Analysis of Randomized Trials.
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.
- Long-Term Effectiveness of Once-Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real-World Study.
- Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety.
- A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists.
- [Effects of liraglutide combined with vitamin D on non-alcoholic fatty liver induced by high fat in mice and its mechanism].
- Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.
- Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis.
- Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.
- A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management.
- Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- Bronchopulmonary dysplasia induced by hyperoxia attenuated by A GLP-1 analog, Liraglutide, by regulating the ACE-2/Ang(1-7)/Mas receptor pathway.
- Comparison chart: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes.
- Noninsulin drugs for type 2 diabetes.
- Systemic Pharmacokinetic Principles of Therapeutic Peptides.
- A renal indication for semaglutide (Ozempic).
- [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]
- Table: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes.
- Drugs for type 2 diabetes.
- [Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day].
- Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.
- Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024.
- Oral delivery of GLP-1 analogues by recombinant Lactococcus lactis restores pancreatic islet structure through intestinal mucosal absorption in diabetic mice.
- Reprint of: Impact of a pharmacist-led weight management service in a cardiology clinic.
- A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses.
- Two Trials of Therapeutics for MASH with Liver Fibrosis.
- The Effect of GLP-1 Receptor Agonists on Autophagy: Insights Gathered from Research Evaluating Neurodegenerative Disorders With These Agents.
- Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity.
- Liraglutide induces enhanced suppression of food intake in mice lacking the growth hormone secretagogue receptor.
- Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure.
- Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist.
- [Peptide hormone analogue-based pharmacotherapy for obesity is effective : What is the evidence on hard end points and the long-term course?]
- Tirzepatide mitigates atherosclerosis progression and modulates oxLDL-mediated proatherogenic effects in macrophages: evidence for M1/M2 homeostasis restoration.
- A RESPONSE TO: "COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES".
- Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control.
- Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
- Glucagon-like peptide-1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity.
- [Promising molecules for treatment of hyperglycemia in patients with type 2 diabetes].
- Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes.
- IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis.